Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Gross Profit (2017 - 2025)

Agios Pharmaceuticals' Gross Profit history spans 8 years, with the latest figure at $18.1 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 91.0% year-over-year to $18.1 million; the TTM value through Dec 2025 reached $47.7 million, up 47.47%, while the annual FY2025 figure was $47.7 million, 47.47% up from the prior year.
  • Gross Profit reached $18.1 million in Q4 2025 per AGIO's latest filing, up from $11.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $18.1 million in Q4 2025 to a low of $493000.0 in Q1 2022.
  • Average Gross Profit over 4 years is $7.3 million, with a median of $6.9 million recorded in 2023.
  • Peak YoY movement for Gross Profit: surged 925.35% in 2023, then increased 1.04% in 2025.
  • A 4-year view of Gross Profit shows it stood at $3.9 million in 2022, then surged by 67.23% to $6.5 million in 2023, then skyrocketed by 45.31% to $9.5 million in 2024, then surged by 91.0% to $18.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Gross Profit are $18.1 million (Q4 2025), $11.2 million (Q3 2025), and $10.8 million (Q2 2025).